{"id":743004,"date":"2023-03-28T07:05:34","date_gmt":"2023-03-28T11:05:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/"},"modified":"2023-03-28T07:05:34","modified_gmt":"2023-03-28T11:05:34","slug":"voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/","title":{"rendered":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., March  28, 2023  (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer\u2019s disease (AD) and from its GBA1 gene therapy program for Parkinson\u2019s disease (PD) and other GBA1-mediated diseases at the AD\/PD\u2122 Conference in Gothenburg, Sweden.<\/p>\n<p>\u201cVoyager continues to advance multiple programs towards the clinic. For our anti-tau antibody program for Alzheimer\u2019s disease, these new preclinical data support our recent selection of VY-TAU01 as the lead development candidate, with an IND filing expected in the first half of 2024,\u201d said Todd Carter, Ph.D., Chief Scientific Officer at Voyager. \u201cFor our GBA1 gene therapy program with Neurocrine for Parkinson\u2019s disease, these new data from a GBA1 loss of function mouse model show effects of three GBA1 gene therapy candidates on multiple endpoints.\u201d<\/p>\n<p>\n        <strong>Selection of an Anti-tau Antibody Candidate Targeting Pathological Tau for the Treatment of Alzheimer&#8217;s Disease (Wencheng Liu, Poster P0643 \/ #1192)<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Tau pathology, and specifically the neuron-to-neuron transmission of pathologic tau, is hypothesized to contribute to cognitive decline and neurodegeneration in AD. Voyager is advancing an anti-tau antibody that blocks pathologic tau spreading for the treatment of AD.<\/li>\n<li>Through multiple immunization campaigns that resulted in a pool of 728 candidates, Voyager identified four novel antibodies that met criteria regarding selectivity, affinity, functional inhibition of pathologic tau in vitro and in vivo, and developability. Three of these antibodies target the same epitope on the C-terminal domain of tau, while one antibody targets the mid-domain; all four are differentiated from N-terminal targeted approaches that have previously failed in clinical trials. All four Voyager antibodies demonstrated robust preclinical efficacy in blocking the spread of pathological tau in a P301S seeding-propagation tauopathy mouse model. Ab01 demonstrated superior efficacy (&gt;70% reduction in tau pathology, as presented at <a href=\"https:\/\/ir.voyagertherapeutics.com\/static-files\/475db8d3-c23d-48db-ac68-8218144947da\" rel=\"nofollow noopener\" target=\"_blank\">AAIC 2022<\/a>), while N-terminal antibodies typically lack efficacy in this model.<\/li>\n<li>Ab01 was humanized. After analysis of multiple humanized Ab01 variants, Voyager selected VY-TAU01 as the development candidate based on a number of developability characteristics, including favorable affinity, activity, specificity, stability, and immunogenicity.<\/li>\n<\/ul>\n<p>\n        <strong>Development of AAV-GBA1 gene replacement therapy via single-IV-delivery with a blood brain barrier penetrant AAV capsid (Charlotte Chung,\u00a0April 1, 2023,\u00a011:55 CET, #1696)<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>The GBA1 gene encodes the lysosomal enzyme \u03b2-glucocerebrosidase (GCase). Mutations in GBA1 decrease GCase activity and cause increased levels of substrate; these mutations are one of the greatest genetic risk factors for PD. Voyager and Neurocrine Biosciences are advancing a GBA1 gene therapy leveraging a novel, intravenously administered, blood-brain-barrier-penetrant TRACER\u2122\u00a0capsid for the treatment of PD.<\/li>\n<li>Voyager has previously demonstrated that this GBA1 gene therapy approach delivered therapeutically-relevant levels of GCase to the brain in mouse efficacy models, following a single intravenous dose using a blood-brain-barrier penetrant capsid.<\/li>\n<li>These new data from additional mouse efficacy studies showed that all three candidates demonstrated significant improvement in several efficacy biomarkers.<\/li>\n<\/ul>\n<p>\n        <strong>About\u00a0Voyager Therapeutics<\/strong><br \/>\n        <br \/>Voyager Therapeutics\u00a0(Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager\u2019s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager\u2019s own pipeline. Voyager\u2019s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer\u2019s disease, amyotrophic lateral sclerosis (ALS), Parkinson\u2019s disease, and Friedreich\u2019s Ataxia, each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9XshLfhtjd_ZcNDKl_G8RbT11Agmt5urNGRGLc5igHPS2QxECh5jYYV3IjCIxZ1ro68X7_yIb-XCoCihLFJeG7m3BcwrCGYIMU915yobpIvEAj0BKzqxibizq0YSXlMY\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.voyagertherapeutics.com<\/u><\/a>.<\/p>\n<p>\n        <em>Voyager Therapeutics<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em> is a registered trademark, and TRACER\u2122 is a trademark, of\u00a0Voyager Therapeutics, Inc.\u00a0<\/em>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward-looking statements.<\/p>\n<p>For example, all statements Voyager makes regarding preclinical data for its antibody programs and AAV-based gene therapy programs, including the presentation of preclinical data at the 2023 AD\/PD Conference; Voyager\u2019s ability to continue to identify and develop anti-tau antibodies; Voyager\u2019s ability to develop its tau antibody program; Voyager\u2019s ability to continue to identify and develop proprietary capsids from its TRACER capsid discovery platform with increased transgene expression, increased blood-brain barrier penetration and increased biodistribution compared to conventional AAV9 and AAV5 capsids; Voyager\u2019s ability to utilize its novel proprietary capsids in its own product development programs; Voyager\u2019s ability to advance its AAV-based gene therapy programs; the preclinical development of its potential development candidates; and Voyager\u2019s ability to utilize its TRACER capsids and antibodies in its product development programs are forward looking.<\/p>\n<p>All forward-looking statements are based on estimates and assumptions by Voyager\u2019s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager\u2019s technology platforms, including Voyager\u2019s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in pre-clinical animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager\u2019s TRACER capsid discovery platform; Voyager\u2019s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform and Voyager\u2019s pipeline developmental programs; the initiation, timing, conduct and outcomes of Voyager\u2019s preclinical studies; the ability to attract and retain talented contractors and employees; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.<\/p>\n<p>These statements are also subject to a number of material risks and uncertainties that are described in Voyager\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Contacts<\/strong><\/p>\n<p>Investors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5CPlhmNYP342t65Z4aA6DWAe14uqUtBXbPwLSYyK-sObK-GtDKomriLlm3J-m8F4gcGwAO99pEbp1hgR8IjB6cl-lnOT2UqsdtOgA0Hxfqg=\" rel=\"nofollow noopener\" target=\"_blank\">Investors@vygr.com<\/a><\/p>\n<p>Media<br \/>Peg Rusconi<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fu5lb9l47AvgoRcyBVFdjIzouC6LiIXeMcFEq1Z9J9pPbXB6wkB95nb5dzFBVLFI33ZCGXmCNLbFVQYfpVmqmSf7X1kUTm_YiQfacV0Q8QYMAvs7XcC2xnE6dMcg3FDf\" rel=\"nofollow noopener\" target=\"_blank\">prusconi@vergescientific.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWQ2OGEzZjctOGExMy00OTg0LWJmNzMtODUwZWYzNjcyZjQ2LTEwMzA0MTM=\/tiny\/Voyager-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer\u2019s disease (AD) and from its GBA1 gene therapy program for Parkinson\u2019s disease (PD) and other GBA1-mediated diseases at the AD\/PD\u2122 Conference in Gothenburg, Sweden. \u201cVoyager continues to advance multiple programs towards the clinic. For our anti-tau antibody program for Alzheimer\u2019s disease, these new preclinical data support our recent selection of VY-TAU01 as the lead development candidate, with an IND filing expected in the first half of 2024,\u201d said Todd Carter, Ph.D., Chief Scientific Officer at Voyager. \u201cFor our GBA1 gene therapy program with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-743004","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer\u2019s disease (AD) and from its GBA1 gene therapy program for Parkinson\u2019s disease (PD) and other GBA1-mediated diseases at the AD\/PD\u2122 Conference in Gothenburg, Sweden. \u201cVoyager continues to advance multiple programs towards the clinic. For our anti-tau antibody program for Alzheimer\u2019s disease, these new preclinical data support our recent selection of VY-TAU01 as the lead development candidate, with an IND filing expected in the first half of 2024,\u201d said Todd Carter, Ph.D., Chief Scientific Officer at Voyager. \u201cFor our GBA1 gene therapy program with &hellip; Continue reading &quot;Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T11:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\\\/PD\u2122 Conference\",\"datePublished\":\"2023-03-28T11:05:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/\"},\"wordCount\":1145,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/\",\"name\":\"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\\\/PD\u2122 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\",\"datePublished\":\"2023-03-28T11:05:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\\\/PD\u2122 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/","og_locale":"en_US","og_type":"article","og_title":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer\u2019s disease (AD) and from its GBA1 gene therapy program for Parkinson\u2019s disease (PD) and other GBA1-mediated diseases at the AD\/PD\u2122 Conference in Gothenburg, Sweden. \u201cVoyager continues to advance multiple programs towards the clinic. For our anti-tau antibody program for Alzheimer\u2019s disease, these new preclinical data support our recent selection of VY-TAU01 as the lead development candidate, with an IND filing expected in the first half of 2024,\u201d said Todd Carter, Ph.D., Chief Scientific Officer at Voyager. \u201cFor our GBA1 gene therapy program with &hellip; Continue reading \"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T11:05:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference","datePublished":"2023-03-28T11:05:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/"},"wordCount":1145,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/","name":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=","datePublished":"2023-03-28T11:05:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MCM1NDk0MjgwIzIwMTg4NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimers-disease-and-gba1-gene-therapy-program-for-parkinsons-disease-at-the-ad-pd-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer\u2019s Disease and GBA1 Gene Therapy Program for Parkinson\u2019s Disease at the AD\/PD\u2122 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=743004"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743004\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=743004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=743004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=743004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}